-------- Original Version -----------
Potential first-in-class, selective nociceptin receptor (NOP) agonist that aims to provide safe, effective treatment for moderate to severe acute pain. Following successful Phase I results earlier this year demonstrating an excellent safety profile, the program has now progressed to Phase II. The randomized, double-blind, double-dummy, placebo- and active controlled, 2-part Phase II trial will evaluate the safety, tolerability and efficacy of this novel NOP agonist in patients post bunionectomy surgery. Grünenthal anticipates reporting results in early 2028.-------- English Version ------------
Potential first-in-class, selective nociceptin receptor (NOP) agonist aimed at treating moderate to severe acute pain. After successful Phase I results demonstrating safety, the program progresses to Phase II, which will evaluate safety, tolerability, and efficacy in patients post bunionectomy. Results are expected in early 2028.-------- Link if available ----------